BioVentrix touts 1st clinical use of Revivent for ischemic cardiomyopathy

BioVentrix said yesterday that its Revivent TC transcatheter ventricular enhancement system saw its 1st clinical use in treating ischemic cardiomyopathy at Berlin, Germany’s Deutsches Herzzentrum. The device was used by interventional cardiologist Dr. Cristoph Klein and Dr. Felix Hennig, with assitance from Dr. Sebastian Kelle, according to BioVentrix. The Revivent system is designed to eliminate the need for cardiopulmonary bypass or incisions in the heart by enabling the placement of small titanium anchors along the heart’s outer surface and along one of the inside walls, according to the San Ramon, Calif.-based company. Bioventrix said that the device was successfully implanted with 2 micro-anchor pairs in a 52-year-old male suffering from ischemic heart failure. The procedure reshaped the left ventricle and the company said it decreased the patient’s left ventricular end systolic volume index. “We are impressed by the immediate impact of the less-invasive Revivent TC system. The patient achieved a 33% reduction in LVESVI and a 15% increase in the Ejection Fraction,” Dr. Kelle said in a prepared statement. “The therapy provides a much-needed option for patients suffering from heart failure due to left ventricular anterior scar, particularly when medical therapy is no longer effective. We are impressed by the immediate improvements and are eager to learn about the long term results of this promising method,” said Dr. Klein said in a p...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Catheters BioVentrix Source Type: news